The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Fc-Optimized Anti-Cd25 For Tumour Specific Cell Depletion - EP3596123

The patent EP3596123 was granted to Cancer Research Technology on Jan 10, 2024. The application was originally filed on Mar 13, 2018 under application number EP18711313A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3596123

CANCER RESEARCH TECHNOLOGY
Application Number
EP18711313A
Filing Date
Mar 13, 2018
Status
Granted And Under Opposition
Dec 8, 2023
Publication Date
Jan 10, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PFIZEROct 4, 2024PFIZERADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2004045512
DESCRIPTIONWO2006108670
DESCRIPTIONWO2008002933
DESCRIPTIONWO2015173384
DESCRIPTIONWO2017174331
DESCRIPTIONWO9007861
DESCRIPTIONWO9311238
INTERNATIONAL-SEARCH-REPORTWO2005115451
INTERNATIONAL-SEARCH-REPORTWO2014145907
OPPOSITIONWO2005115451
OPPOSITIONWO2014145907
OPPOSITIONWO2017174331
OTHEREP3596123

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents